Chemotherapy with adjuvant nivolumab versus placebo for GEJ cancer

Syed A. Ahmad, Chief of Surgical Oncology at The University of Cincinnati, made the following post on X:

“Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5)⁦ .”

Additional information.
Source: Syed A. Ahmad/X

Drugs

cancer chemotherapy gastric cancer gastro-oesophageal junction cancer Hyun Cheol Chung Jen-Shi Chen Jiafu Ji Jong Gwang Kim Keun Won Ryu Li-Tzong Chen Li-Yuan Bai lymph-node dissection Masanori Terashima Min-Hee Ryu Mitsuru Sasako Narikazu Boku nivolumab Norimasa Fukushima OncoDaily Oncology Shinichi Sakuramoto Shunsuke Hagihara Sun Young Rha Syed A. Ahmad Ta-Sen Yeh Tae Yong Kim Takanobu Yamada Takashi Nakada Takeshi Omori The University of Cincinnati Yasunori Nishida Yoon-Koo Kang Yoshinori Hirashima Young Woo Kim